140 related articles for article (PubMed ID: 8767071)
1. [Effect of factor VIII concentrates of very high purity on CD4+ cell count in hemophiliacs infected with HIV].
Molina Alejandro R; Lorenzo Herrero JI; Haya Guaita S; Querol Fuentes F; Aznar Lucea JA
Rev Clin Esp; 1996 Jun; 196(6):365-9. PubMed ID: 8767071
[TBL] [Abstract][Full Text] [Related]
2. CD4 cells in HIV-1 infected hemophiliacs: effect of factor VIII concentrates.
Goldsmith JM; Deutsche J; Tang M; Green D
Thromb Haemost; 1991 Oct; 66(4):415-9. PubMed ID: 1839091
[TBL] [Abstract][Full Text] [Related]
3. CD4+ counts before and after switching to monoclonal high-purity factor VIII concentrate in HIV-infected haemophilic patients.
Sabin C; Pasi J; Phillips A; Elford J; Janossy G; Lee C
Thromb Haemost; 1994 Aug; 72(2):214-7. PubMed ID: 7831654
[TBL] [Abstract][Full Text] [Related]
4. Immune status of asymptomatic HIV-infected hemophiliacs: randomized, prospective, two-year comparison of treatment with a high-purity or an intermediate-purity factor VIII concentrate.
Mannucci PM; Gringeri A; de Biasi R; Baudo F; Morfini M; Ciavarella N
Thromb Haemost; 1992 Mar; 67(3):310-3. PubMed ID: 1353642
[TBL] [Abstract][Full Text] [Related]
5. [Evolution of CD4 and CD8 lymphocyte subsets in HIV seronegative and seropositive hemophiliacs].
Lorenzo JI; Molina R; Aznar JA
Sangre (Barc); 1993 Feb; 38(1):5-11. PubMed ID: 8470035
[TBL] [Abstract][Full Text] [Related]
6. [The effect of the type of factor VIII concentrate on the CD4 lymphocyte count in hemophiliacs with human immunodeficiency virus infection: the results of a meta-analysis].
Montoro Ronsano JB; Oliveras Martín J; Tusell Puigbert JM
Med Clin (Barc); 1994 Nov; 103(18):690-4. PubMed ID: 7808075
[TBL] [Abstract][Full Text] [Related]
7. High versus ultra-high purity factor VIII concentrate therapy: prospective evaluation of immunological and clinical parameters in HIV seronegative and seropositive hemophiliacs.
Varon D; Schulman S; Dardik R; Barzilai A; Bashari D; Martinowitz U
Thromb Haemost; 1994 Sep; 72(3):359-62. PubMed ID: 7855784
[TBL] [Abstract][Full Text] [Related]
8. Effects of factor VIII concentrates on the immune system of patients with hemophilia.
Mannucci PM
Thromb Haemost; 1995 Jul; 74(1):437-9. PubMed ID: 8578501
[TBL] [Abstract][Full Text] [Related]
9. Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status.
Seremetis SV; Aledort LM; Bergman GE; Bona R; Bray G; Brettler D; Eyster ME; Kessler C; Lau TS; Lusher J
Lancet; 1993 Sep; 342(8873):700-3. PubMed ID: 8103820
[TBL] [Abstract][Full Text] [Related]
10. [Hemophiliacs with HIV. Slower progression of the infection among younger patients and at higher dosages of factor concentrates].
Astermark J; Berntorp E; Stigendal L; Johnsson H
Lakartidningen; 1998 Jan; 95(1-2):48-50. PubMed ID: 9458646
[TBL] [Abstract][Full Text] [Related]
11. Very-high-purity versus intermediate-purity factor VIII in human immunodeficiency virus-positive hemophiliacs: conclusions of a prospective 3-year study. Monoclate Study Group.
Seremetis SV
Semin Hematol; 1993 Oct; 30(4 Suppl 5):10-3. PubMed ID: 7903480
[No Abstract] [Full Text] [Related]
12. New protocol for immune tolerance induction in acquired hemophilia.
Nemes L; Pitlik E
Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
[TBL] [Abstract][Full Text] [Related]
13. Effect of intermediate- and high-purity factor VIII concentrates on immune function in HIV-seropositive haemophiliacs as assessed by quantitative CD 4 counts.
Deitcher SR; Tuller J; Dugdale M
Haemophilia; 1997 Oct; 3(4):265-9. PubMed ID: 27214862
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of the intron 22 inversion of the factor VIII gene and inhibitor development in Polish patients with severe hemophilia A.
Sawecka J; Skulimowska J; Windyga J; Lopaciuk S; Kościelak J
Arch Immunol Ther Exp (Warsz); 2005; 53(4):352-6. PubMed ID: 16088320
[TBL] [Abstract][Full Text] [Related]
15. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates.
de Biasi R; Rocino A; Papa ML; Salerno E; Mastrullo L; De Blasi D
Thromb Haemost; 1994 May; 71(5):544-7. PubMed ID: 8091377
[TBL] [Abstract][Full Text] [Related]
16. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
Deitcher SR; Tuller J; Johnson JA
Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955
[TBL] [Abstract][Full Text] [Related]
17. Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product.
Yee TT; Williams MD; Hill FG; Lee CA; Pasi KJ
Thromb Haemost; 1997 Sep; 78(3):1027-9. PubMed ID: 9308748
[TBL] [Abstract][Full Text] [Related]
18. Decrease of CD4 cell number and function in HIV-seropositive hemophiliacs in a longitudinal study.
Knutsen AP; Bouhasin JD; Joist JH; Scrivner D; Mueller KR; Gioia K; Janney S
Ann Allergy; 1989 Sep; 63(3):189-94. PubMed ID: 2528308
[TBL] [Abstract][Full Text] [Related]
19. The effect of monoclonal or ion-exchange purified factor VIII concentrate on HIV disease progression: a prospective cohort comparison.
Hay CR; Ludlam CA; Lowe GD; Mayne EE; Lee RJ; Prescott RJ; Lee CA
Br J Haematol; 1998 Jun; 101(4):632-7. PubMed ID: 9674733
[TBL] [Abstract][Full Text] [Related]
20. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
